Healthy Aging & Longevity

Tesamorelin

A stabilized GHRH analog with the most substantial clinical research base of the growth hormone secretagogues.

Baseline Labs Generally RequiredInjectableEstablished evidenceOff-Label
  • Physician reviewed
  • 503A pharmacy compounded
  • Patient-specific prescription

Formats & pricing

  • 2mg vial — reconstituted injectable$230
Start my CareSee how it works

Pricing reflects the compounded preparation and physician review. Final therapy and dosing are determined only after your intake is reviewed.

Overview

What is Tesamorelin?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone. It is distinguished from other secretagogues by a comparatively developed clinical literature, particularly regarding visceral adipose tissue.

Mechanism

How it works

Tesamorelin binds pituitary GHRH receptors to stimulate endogenous growth hormone secretion, which in turn raises IGF-1. Research has focused notably on its effect on visceral rather than subcutaneous fat.

Wellness support

Potential wellness support areas

These areas are commonly discussed within wellness-focused protocols. They are educational statements, not medical claims or guarantees of outcome.

  • Explored for visceral adipose tissue reduction
  • Discussed within metabolic health protocols
  • Potential support for body composition
  • Commonly tracked with IGF-1 and metabolic panels

Administration

Format & dosing

Once-daily subcutaneous injection, usually at night. Protocols are typically longer-running with periodic lab reassessment.

Labs & monitoring

Labs, testing & monitoring

Your physician determines the final testing requirements for Tesamorelin after reviewing your intake. The panels below are what is commonly reviewed for this therapy — they are educational guidance, not a fixed requirement.

Bloodwork status

Baseline Labs Generally Required

Commonly reviewed at baseline

  • IGF-1
  • Comprehensive metabolic panel (CMP)
  • Fasting glucose and A1c
  • Lipid panel
  • Thyroid panel (TSH, free T4)

Follow-up & monitoring

IGF-1 and glycemic markers are typically reassessed at 8 to 12 weeks, then periodically while therapy continues.

Who may not be a candidate

  • Pregnancy or nursing
  • Active malignancy without oncology clearance
  • Known hypersensitivity to the preparation
  • Active pituitary disease
  • Uncontrolled diabetes

Medication interactions

Your physician reviews all prescriptions, supplements, and over-the-counter medications during intake before anything is prescribed.

Safety

Safety & considerations

Compounded preparations are not FDA-approved products. Not appropriate with active malignancy. Glucose tolerance should be monitored in at-risk patients.

Regulatory status: Off-Label. Evidence level: Established. Eligibility, dosing, laboratory requirements, and follow-up care are determined exclusively by a licensed physician after review of your history.

Physician reviewed

Every protocol is approved by a licensed physician.

503A compounded

Prepared by licensed US compounding pharmacies.

Patient-specific Rx

Prescriptions are issued in your name only.

No membership

No concierge fee and no subscription to browse or begin.

Ready when you are

Find out what your body is actually asking for.

Fill out a short intake form and our care team will build a plan grounded in your labs — not a guess from a supplement aisle.